View More Recent Stories
-
Applied Therapeutics Inc. (APLT) Appoints John H. Johnson as Executive Chairman
-
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
-
Verastem Oncology (VSTM) Provides a Clinical Update for RAMP 203 Trial
-
Verastem (VSTM) PT Raised to $9 at Mizuho
-
Verastem (VSTM) defended at Truist, 'see the weakness as an overreaction and continue to see commercial potential'
-
Verastem (VSTM) PT Lowered to $15 at Truist Securities
-
Verastem (VSTM) PT Lowered to $7 at H.C. Wainwright
-
Verastem Oncology (VSTM) Misses Q2 EPS by 61c
-
Verastem Oncology (VSTM) Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
-
Verastem (VSTM) PT Lowered to $7 at Mizuho
-
Verastem (VSTM) PT Lowered to $7 at B.Riley
-
Verastem Oncology (VSTM) Announces Proposed Share Offering
-
Verastem (VSTM) PT Lowered to $18 at Truist Securities

